Share This Page
Drugs in ATC Class P02CB
✉ Email this page to a colleague
Drugs in ATC Class: P02CB - Piperazine and derivatives
| Tradename | Generic Name |
|---|---|
| ANTEPAR | piperazine citrate |
| BRYREL | piperazine citrate |
| MULTIFUGE | piperazine citrate |
| >Tradename | >Generic Name |
Market dynamics and patent landscape for ATC Class P02CB (piperazine and derivatives)
ATC Class P02CB covers anthelmintics based on piperazine (and related derivatives). Patent protection in this therapeutic segment is typically limited to older primary compounds and older formulation or manufacturing patents, with many jurisdictions largely relying on off-patent competition. Market dynamics are dominated by (1) low-cost generic supply, (2) procurement-driven tendering in public health systems, (3) shelf-life and stability constraints for pediatric dosing, and (4) packaging/strength changes that can support limited secondary IP.
No drug-specific patent estate, Orange Book/Biosimilar dataset, or litigation docket could be reliably mapped to “P02CB” as a single monolithic product category because ATC grouping includes multiple actives and, in practice, multiple dosage presentations. A complete, accurate market-and-IP readout therefore cannot be produced for the whole class without collapsing distinct actives into one dataset.
What market dynamics drive sales of ATC P02CB piperazine anthelmintics?
ATC P02CB products generally trade on price and supply continuity rather than differentiation. The commercial model is procurement-heavy, with formulary inclusion driven by efficacy evidence in labeled indications, pediatric usability, and compliance with national procurement specifications.
How do tendering and public procurement affect piperazine and derivatives pricing?
- Governments and major purchasers set price caps through national formularies and batch tenders.
- Volume concentration favors established generic suppliers with reliable regulatory submissions and manufacturing scale.
- Switchovers are slow when reimbursement and tender contracts are multi-year.
What drives product differentiation in piperazine-based dosing?
Differentiation is mostly “developability” and “usability”:
- Pediatric dosing accuracy through liquid/syrup concentration choices.
- Taste-masking and viscosity for better adherence.
- Stability and shelf-life under local distribution temperature profiles.
- Packaging formats aligned to dosing guidelines.
What is the competitive landscape in P02CB?
- Competition is primarily generic.
- Brand presence, where it exists, often persists only in specific geographies or via packaging/strength variants rather than new MOA breakthroughs.
- Barriers to entry tend to be regulatory and quality-system driven rather than patent driven.
Which active ingredients fall under ATC P02CB and how does that change the patent landscape?
ATC P02CB is a class label, not a single patent portfolio. Patent coverage depends on the specific active ingredient and salt/derivative, plus route and formulation.
Why is “P02CB patent landscape” not one estate?
Because the class can include:
- piperazine (and salts),
- piperazine derivatives with distinct chemical identity,
- and regionally marketed variants that can shift what is considered “in class.”
Each distinct active ingredient usually has:
- its own core compound patent history,
- its own formulation/combination secondary patents,
- and its own regulatory dossier that determines generic entry timing.
What patents protect piperazine and derivatives for anthelmintic use?
For older anthelmintics in general, the patent pattern is typically:
- early compound patents (most have expired long ago),
- later formulation or manufacturing process patents (often expired as well or with narrow remaining coverage depending on jurisdiction),
- occasional pediatric and stability-related reformulations (limited and short-lived).
How strong is the patent estate for older piperazine anthelmintics?
- Usually weak for “first generic” entry because core compound patents are long expired.
- Secondary patents, where they exist, are often:
- narrow to a specific liquid concentration or excipient system,
- narrow to a manufacturing step,
- or limited by jurisdiction and term.
What formulation patents are most common in anthelmintic pediatric dosing?
- Liquid formulations with specified concentration ranges and excipient systems.
- Stability and shelf-life extensions through packaging or process control.
- Bioavailability or dissolution specifications tied to manufacturing method.
What method-of-manufacture patents matter for generic entry?
- Granulation, milling, polymorph control (if relevant to the solid form),
- filtration/sterilization or solvent recovery controls (for liquids),
- and in-process controls that affect impurity profiles.
When does exclusivity end for piperazine and derivatives anthelmintics in key markets?
Exclusivity is not class-wide in a way that can be computed without the specific listed product(s) and their FDA/EMA/National authorization history. For older anthelmintics, the practical commercial expectation is that:
- patent barriers are mostly gone,
- remaining regulatory exclusivity depends on whether any product-specific reformulation or new legal status was granted recently in a jurisdiction.
What timelines typically govern generic entry for off-patent anthelmintics?
- For small-molecule generics, entry is commonly constrained by:
- data exclusivity on the originator’s regulatory dossier (if still applicable),
- patent remainder on specific formulations or manufacturing methods,
- and any pediatric-use label changes tied to later regulatory submissions.
What Orange Book status applies to ATC P02CB piperazine products?
An Orange Book mapping requires the exact NDA/ANDA identifiers for the marketed piperazine products. ATC class labels do not uniquely correspond to Orange Book listings. A complete status report cannot be produced for “P02CB” as a class without selecting specific products.
What Paragraph IV challenges exist for piperazine and derivatives anthelmintics?
Paragraph IV disputes track specific ANDA filings and listed patents per product. Because ATC P02CB includes multiple potential actives and dosage forms, a reliable Paragraph IV litigation summary cannot be generated at the class level without product-to-patent mapping.
What generic entry risks exist for piperazine-based anthelmintics?
Generic entry risks in this space are typically:
- patent-claim risk on formulation/process patents that remain jurisdiction-specific,
- regulatory risk around impurity limits and stability specifications,
- and tender/contract risk where switching suppliers is procedurally slow.
How do formulation variants change risk?
- If a tender requires a particular concentration, dosage form, or excipient profile, generics may need to align closely to avoid non-compliance even if core API patents are expired.
- Shelf-life and distribution stability can be decisive in real-world award decisions.
How does piperazine anthelmintic competition compare with other anthelmintic classes (e.g., benzimidazoles, levamisole, ivermectin)?
Relative to many modern anthelmintics, piperazine-based drugs generally face:
- less IP friction and earlier generic saturation,
- lower unit prices,
- and a narrower differentiation surface focused on pediatric administration and availability.
That comparison matters commercially because it shapes expectations for:
- R&D ROI (limited IP tail),
- and licensing strategies (often not worth acquiring broad “class IP” claims).
What patent litigation affects piperazine and derivatives anthelmintics?
Class-level patent litigation cannot be mapped without identifying:
- the specific branded/generic products and
- the listed patents asserted in suits or settlements.
What licensing or settlements are typical for generic entry in older anthelmintics like P02CB?
Where settlements occur in off-patent anthelmintics, they usually involve:
- narrow formulation/process patents tied to particular dosage forms,
- and sometimes combination product patents if a derivative is used in multi-active regimens.
At class level, there is no single licensing pattern that can be asserted with accuracy.
What regulatory pathway differences matter for piperazine and derivatives generics?
For generics, pathway choice depends on the original product dossier and local regulation:
- bioequivalence expectations may be lower for certain formulations but not uniform across jurisdictions,
- liquid products are often more scrutinized for stability and impurity control.
What manufacturing/IP barriers are most relevant?
- Controlled impurity profiles and solvent residues (where synthesis/processing uses solvents).
- Quality system alignment to meet tender-grade specifications.
- Consistency of concentration and dosing accuracy.
Key takeaways
- ATC Class P02CB is too broad to produce an accurate patent estate and litigation map without tying to specific active ingredients and marketed dosage forms.
- Commercial outcomes are dominated by tendering, pediatric usability, stability, and availability rather than active-invention differentiation.
- Patent barriers, where they exist, are usually narrow and formulation or process oriented, with limited ability to sustain long-term exclusivity across jurisdictions.
FAQs
- Which marketed piperazine products are currently listed in national formularies under ATC P02CB, and what dosage forms drive demand?
- Do piperazine formulations have unique stability or impurity constraints that commonly delay generic approvals?
- Are there active patents on specific piperazine salts or derivatives that can block generic entry in the EU or UK?
- How do tender specifications (concentration, syrup base, shelf-life requirements) impact practical generic substitutability even after API patent expiry?
- What is the typical patent strategy for late-stage reformulation of off-patent small-molecule anthelmintics in pediatric dosing?
References (APA)
- World Health Organization. (n.d.). ATC classification system. World Health Organization.
More… ↓
